AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02267070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
Study NCT01986738 — intervention group
Intervention type: RADIATION
Intervention: Standard Radiation Therapy
Description: Radiotherapy will be planned and delivered according to institutional standard of care.
Study NCT04480775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: transversus abdominis plane block with bupivacain and triamicinolone
Study NCT04480775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: transversus abdominis plane block with bupivacaine and methylprednisolone
Study NCT04480775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: transversus abdominis plane block with bupivacaine alone
Study NCT04480775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: transversus abdominis plane block with bupivacaine alone
Study NCT01986738 — intervention group
Intervention type: DEVICE
Intervention: Active Breathing Control Device (ABC)
Study NCT01986738 — intervention group
Intervention type: DEVICE
Intervention: Computed Tomography Scan (CT)
Study NCT01918917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: intraarticular
Study NCT01918917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intraarticular 1 ml (100 mcg)
Study NCT01918917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenously, patient-controlled analgesia
Study NCT01744470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus targeted half-dose
Study NCT01744470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus targeted plain dose
Study NCT03042923 — intervention group
Intervention type: DRUG
Intervention: lactulose:mannitol (L:M) oral challenge
Study NCT02037620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-6-5 Specify electrode
Study NCT02037620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restore Advance Pulse Generator
Study NCT03979534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low protein diet
Description: Patients will be managed with a restricted protein intake (controlled protein diets with a mean target at 0.6 g / kg / day of protein, according to a choice of dietary approaches, adapted to the situation of each patient).
Study NCT01839097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~* Cohort 1: belinostat 1000 mg/m2 IV on Day 1~* Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~* Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~* Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~* Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5
Study NCT01839097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat.
Study NCT03253445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).
Study NCT03253445 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
Study NCT03308175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flat fixed anterior bite plane
Description: It causes unlocking mandible from deep bite in growing females
Study NCT03308175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified inclined fixed anterior bite plane
Description: It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
Study NCT02212652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 10,000 IU of VitD3 daily (one gel daily)
Study NCT02212652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gummy button placebo, which will appear very similar to the vitamin D supplement.
Study NCT02212652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
Study NCT02212652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
Study NCT04703205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3 MG
Description: Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)
Study NCT04703205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
Study NCT01818531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor canal block
Study NCT01818531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar plexus block
Study NCT03664102 — intervention group
Intervention type: DEVICE
Intervention: Cor Knot
Description: Heart valve replacement with or without the use of automated fastener device Cor Knot
Study NCT05963477 — intervention group
Intervention type: PROCEDURE
Intervention: laparatomy
Description: all abdominal procedures which are approached by different incisions
Study NCT00513877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT00513877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT01093469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atopiclair Nonsteroidal Cream
Study NCT01093469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment
Study NCT01093469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram
Study NCT03274895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHMB 0.08%
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
Study NCT03274895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propamidine 0.1%
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
Study NCT03274895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
Study NCT03274895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PHMB 0.02%
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
Study NCT00477490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin acetate
Description: Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
Study NCT00477490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
Study NCT01223547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants are taught the principles of carb counting
Study NCT01223547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.
Study NCT04247477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation strategy
Description: Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)
Study NCT01646177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03292185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Study NCT01646177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg etanercept
Description: Administered SC
Study NCT01646177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab
Description: Administered SC
Study NCT01068665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study NCT01068665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study NCT01546077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of perineural catheters with Hydrolocalization technique using
Description: Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
Study NCT01373580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Raindrop Near Vision Inlay
Description: The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
Study NCT01613482 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: cerebral prophylactic radiation
Description: 24Gy, 12 fractions of 2 Gy
Study NCT01613482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Weekly, 2mg/kg of corporal weight
Study NCT01613482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Weekly, 2mg/kg of corporal weight
Study NCT01613482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other chemotherapy in association with Trastuzumab
Description: other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
Study NCT01613482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other chemotherapy in association with Trastuzumab
Description: other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
Study NCT02882425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag for intravenous use
Description: Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
Study NCT02882425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag for oral use
Description: Tablet containing 200 µg of selexipag
Study NCT03292185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Study NCT02199158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Laser Peripheral Iridoplasty
Description: ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
Study NCT01584960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: endurance training
Description: 2 years of home-based endurance training
Study NCT03846453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HL036 Ophthalmic Solution
Description: HL036 Ophthalmic Solution
Study NCT03846453 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vehicle solution
Study NCT02888574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
Study NCT03292185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh
Study NCT02888574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study NCT04210921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi .
Study NCT04210921 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The park sham needle
Description: When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin.
Study NCT02378038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNT2258
Study NCT03271853 — intervention group
Intervention type: DEVICE
Intervention: Sentinel BreastScan II
Description: The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
Study NCT03697122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Humidified Breathing Circuit and Forced Air Blanket
Description: Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming.
Study NCT00807339 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation
Description: Dose escalation three consecutive treatments
Study NCT00807339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberKnife Robotic Radiosurgery System
Study NCT01063998 — intervention group
Intervention type: OTHER
Intervention: Urine Marker
Description: Urinary KIM-1 measurements
Study NCT00517023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleuth Implantable Loop Recorder
Description: ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
Study NCT00517023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other
Description: Routine care and tests usually offered for syncope patients.
Study NCT03176147 — intervention group
Intervention type: OTHER
Intervention: Iron deficiency anemia
Description: The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
Study NCT01353118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: Optimise glucose control within 3 months before operation
Study NCT03030677 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pectoralis II block & catheter without Lidocaine dissection
Description: B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
Study NCT03030677 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pectoralis II block & catheter with Lidocaine dissection
Description: B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
Study NCT03030677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: catheter insertion
Description: catheter insertion after Lidocaine dissection
Study NCT00650819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Description: ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
Study NCT00650819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
Study NCT00650819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
Study NCT01900041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantovigar
Description: 1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
Study NCT01900041 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Minoxidil 2% only
Description: 1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
Study NCT01900041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil 2% only
Description: 1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
Study NCT03790852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal injection
Study NCT03421379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon Nasal Powder
Description: Administered intranasally
Study NCT03421379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon Hydrochloride Solution
Description: Administered IM
Study NCT03571607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pupil reflex dilation measurement (PRD)
Description: Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupil reflex dilation measurement (PRD)
Description: Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pupil reflex dilation measurement (PRD)
Description: Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PPI (Pupillary Pain Index)
Description: Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPI (Pupillary Pain Index)
Description: Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
Study NCT04000126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PPI (Pupillary Pain Index)
Description: Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
Study NCT04000126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation